Shares of TG Therapeutics rose approximately 10% [1] on Wednesday after the company released Phase 1 trial data for an injectable version of its drug BRIUMVI.
The results are significant because a subcutaneous formulation could offer a more convenient administration method for patients. A quarterly dosing regimen may provide a commercial advantage over existing treatment options for multiple sclerosis.
The early-stage trial evaluated the subcutaneous formulation of ublituximab-xiiy. The company said the data demonstrated supportive pharmacokinetic and pharmacodynamic results [2], [3]. This suggests the drug is pharmacologically viable when delivered via injection rather than the standard infusion method.
TG Therapeutics is continuing to advance its clinical pipeline. The company said it expects to release Phase 3 trial data by year-end 2026 [4].
Briumvi has previously shown strong efficacy in treating multiple sclerosis. In the Phase 3 ULTIMATE I and II trials, the drug demonstrated a 56.7% reduction in the annualized relapse rate compared to teriflunomide [5].
Investors responded to the Wednesday announcement with optimism, driving the stock price up on the NASDAQ [1]. The company is positioning the injectable version to improve patient access, and adherence, through reduced clinic visits.
“Shares of TG Therapeutics rose approximately 10% on Wednesday”
The shift from intravenous infusions to subcutaneous injections represents a broader trend in biotechnology to move chronic treatments from clinical settings to home administration. If TG Therapeutics successfully moves this formulation through later-stage trials, it could increase the market share of Briumvi by reducing the burden on patients and healthcare infrastructure.
